Ad
related to: microbiome therapeutics and patent protection
Search results
Results from the WOW.Com Content Network
Pharmacomicrobiomics, proposed by Prof. Marco Candela for the ERC-2009-StG project call (proposal n. 242860, titled "PharmacoMICROBIOMICS, study of the microbiome determinants of the different drug responses between individuals"), and publicly coined for the first time in 2010 by Rizkallah et al. (from Ramy K. Aziz research group), is defined ...
Drug Price Competition and Patent Term Restoration Act; Long title: An Act to amend the Federal Food, Drug, and Cosmetic Act to revise the procedures for new drug applications, to amend title 35, United States Code, to authorize the extension of the patents for certain regulated products, and for other purposes.
Mayo v. Prometheus, 566 U.S. 66 (2012), was a case decided by the Supreme Court of the United States that unanimously held that claims directed to a method of giving a drug to a patient, measuring metabolites of that drug, and with a known threshold for efficacy in mind, deciding whether to increase or decrease the dosage of the drug, were not patent-eligible subject matter.
The rapid enrolment reflects patient interest and the significant need for innovative IBS therapies that target microbiome imbalances, and we look forward to reporting topline data early next year.” About EnteroBiotix . EnteroBiotix is a clinical-stage biotechnology company developing therapeutics to treat gastrointestinal and hepatic diseases.
The accession to the Treaty is open to States party to the Paris Convention for the Protection of Industrial Property of 1883. The African Regional Industrial Property Organization (ARIPO), the Eurasian Patent Organization (EAPO) and the European Patent Organisation (EPO) have filed a declaration of acceptance under Article 9(1)(a) [6] of the ...
OpenBiome is a nonprofit health research organization based in Massachusetts accelerating research on the human microbiome. They partner with leading researchers, clinicians and innovators to advance and ensure access to novel and affordable microbiome therapeutics.
Design of engineered live bacterial therapeutics [1]. Bacterial therapy is the therapeutic use of bacteria to treat diseases.Bacterial therapeutics are living medicines, and may be wild type bacteria (often in the form of probiotics) or bacteria that have been genetically engineered to possess therapeutic properties that is injected into a patient.
Chakrabarty, upheld the first patent on a newly created living organism, a bacterium for digesting crude oil in oil spills. The patent examiner for the United States Patent and Trademark Office had rejected the patent of a living organism, but Chakrabarty appealed. As a rule, raw natural material is generally rejected for patent approval by the ...
Ad
related to: microbiome therapeutics and patent protection